A Study on Mass-Screening Test for Detection of Bladder Cancer by Automated Urine Cytology

自动尿细胞学检测膀胱癌大规模筛查试验的研究

• 批准号: 01570907
• 负责人: TACHIBANA Masaaki
• 金额: $ 0.45万
• 依托单位: School of Medicine, Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1989
• 资助国家: 日本
• 起止时间: 1989 至 1990
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-01570907/
• 关键词: Automated Urine Cytology; Human Bladder Cancer; Flow cytometry; DNA; Bromodeoxyuridine; Computer Assisted Image Analysis; マススクリ-ニング; Automated Urine Cytology; Human Bladder Cancer; Flow cytometry; DNA; Bromodeoxyuridine; Computer Assisted Image Analysis; マススクリ-ニング

A direct correlation clearly exists between the presence of abnormal deoxyribonucleic acid (DNA) contents within the tumors and the degree of clinical malignancy in several tumor system. The modern flow cytometric technique can measure DNA in complex cell mixtures via individual cell examination at the tremendous rate. Therefore, this analysis can be uterized quantitative and objective detection of malignant cells in urine sample which can be applied to automated urine cytology. In order to evaluate flow cytometric DNA measurement (FCM) of bladder washing in the diagnosis of bladder cancer, the sensitivity of voided urine cytology, bladder washing cytology and bladder washing FCM was tested. The results from 76 samples from 56 patients with histologically proven transitional cell carcinoma of the bladder, FCM is more sensitive than voided urine cytology and/or bladder washing cytology. Also was found that FCM may indicate urothelial neoplasia before it is apparent on urine cytology, es … More pecially against a background of inflammation. Therefore, FCM is thought to be valuable for case finding in suspected population or for follow-up cases with diagnosed bladder cancer. However, potential developments of, and further improvements is needed since the sensitivity for detecting low-grade-tumor was low. In this regard, flow cytometric DNA/bromodeoxyuridine (BrdU) bivariate analysis was performed whether the technique can provide further information on the malignant potential of bladder cancer than DNA analysis alone. Results from a total of 56 bladder tumors, DNA/BrdU two-color FCM can provide an objective parameter for quantification of the malignant potential of bladder cancers. Thus, FCM technique is advantageous than classical cytology because of ; 1) higher sensitivity, 2) early predictability and 3) more objective and quantitative analysis. Meanwhile, malignant tumor cell detection by computer-assisted image analysis was performed. So far, the method can differentiate white blood cell, red blood cell, epithelial cell and crystals. Also, high-grade tumor cell can be identified because of high-nuclear/cell ration. However, difficulty of clarification on low-grade tumor cell were found. This result indicate that further identification of tumor-specific markers are needed for improvement of this method as routine laboratory procedures. Less

在肿瘤内部异常的脱氧核糖核酸（DNA）含量和几个肿瘤系统中临床恶性肿瘤的程度之间存在直接相关性。现代流式细胞仪技术可以以巨大的速度通过单个细胞检查中的复杂细胞混合物中的DNA测量。因此，该分析可以是尿液样品中恶性细胞的定量和客观检测，可以应用于自动尿细胞学。为了评估膀胱癌诊断中膀胱洗涤的流式细胞仪DNA测量（FCM），测试了尿液细胞学，膀胱洗涤细胞学细胞学和膀胱洗涤FCM的敏感性。来自56例历史悠久的膀胱过渡细胞癌的76个样品的结果比变白尿细胞学和/或膀胱洗涤细胞学更敏感。还发现，FCM可能在尿细胞学上明显地表明尿路上皮肿瘤，更具体地说是在炎症背景下。因此，FCM被认为对于可疑人群或诊断性膀胱癌的随访病例而言是有价值的。但是，由于检测低级肿瘤的灵敏度较低，因此需要对潜在的发展和进一步的改进。在这方面，流式细胞仪DNA/溴脱氧尿苷（BRDU）双变量分析是否可以与单独的DNA分析相比，该技术是否可以提供有关膀胱癌的恶性潜力的进一步信息。总共56个膀胱肿瘤的结果，DNA/BRDU两色FCM可以提供一个客观参数，以定量膀胱癌的恶性潜力。这就是FCM技术比经典细胞学有利； 1）较高的灵敏度，2）早期可预测性和3）更多客观和定量分析。平均值，进行了通过计算机辅助图像分析进行恶性肿瘤细胞检测。到目前为止，该方法可以区分白细胞，红细胞，上皮细胞和晶体。同样，由于高核/细胞评估，可以鉴定出高级肿瘤细胞。然而，很难在低度肿瘤细胞上进行澄清。该结果表明，需要进一步识别肿瘤特异性标记，以改善该方法作为常规实验室程序。较少的